Subscribe
shutterstock_96721225_steve_heap
Steve Heap / Shutterstock.com
25 March 2021Big PharmaAlex Baldwin

Supreme Court denies MS treatment patent petition

The US Supreme Court has denied a petition from Argentum Pharmaceuticals to review a Federal Circuit ruling covering a multiple sclerosis treatment patent.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Mylan scores multiple sclerosis patent win over Biogen
23 June 2020   Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.
Americas
PTAB instigates interference on Biogen multiple sclerosis treatment
15 April 2015   The US Patent Trial and Appeal Board has instigated an interference proceeding between Biogen and Forward Pharma to determine who first invented a treatment for multiple sclerosis.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Mylan scores multiple sclerosis patent win over Biogen
23 June 2020   Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.
Americas
PTAB instigates interference on Biogen multiple sclerosis treatment
15 April 2015   The US Patent Trial and Appeal Board has instigated an interference proceeding between Biogen and Forward Pharma to determine who first invented a treatment for multiple sclerosis.

More on this story

Americas
Mylan scores multiple sclerosis patent win over Biogen
23 June 2020   Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.
Americas
PTAB instigates interference on Biogen multiple sclerosis treatment
15 April 2015   The US Patent Trial and Appeal Board has instigated an interference proceeding between Biogen and Forward Pharma to determine who first invented a treatment for multiple sclerosis.

More features

Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court
Cooley adds ex-Gowling partner